<DOC>
	<DOCNO>NCT02515838</DOCNO>
	<brief_summary>A Multi-Centre , Phase II , Randomized , Double-Blind , Placebo-Controlled Study investigate Efficacy Safety Sevuparin Infusion Management Acute Vaso-Occlusive Crisis ( VOC ) Subjects Sickle-Cell Disease ( SCD ) .</brief_summary>
	<brief_title>Sevuparin Infusion Management Acute VOC Subjects With SCD</brief_title>
	<detailed_description>This phase II , multi-centre , randomize , double-blind , placebo-controlled study design ass preliminary efficacy , safety pharmacokinetics ( PK ) 2-7 day continuous IV administration sevuparin management acute VOC subject SCD . Adults adolescents ≥ 12 year age randomize treatment sevuparin placebo ( ratio 1:1 ) .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>Sign write informed consent ( adult , parent ) assent ( adolescent ) Male female , age 1250 year . Diagnosis Sickle cell disease Subjects admit acute , painful VOC treated/or treat parenteral opioid analgesia . Expectancy need hospitalization least 48 hour . Be least 1 year postmenopausal , surgically sterile , Women Child Bearing Potential ( WOCBP ) , e.g . follow menarche practice effective method birth control Severe hepatic failure/disease , abnormal liver enzyme test history hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) Abnormal conjugate ( direct ) bilirubin 3 fold ULN History clinically significant bleed vital organ Current clinically significant bleeding , judge investigator Current use acetylsalicylic acid ( ASA ) , antiplatelet therapy , anticoagulant therapy Abnormal coagulation laboratory value A platelet count &lt; 75,000/µL . BMI &gt; 35 Subjects 5 hospitalization VOC last 6 month Evidence acute SCD complication VOC screen The use strong opioids &gt; 3 consecutive day last 15 day present hospital History chronic drug abuse . Renal dysfunction Known infection ( positivity ) human immunodeficiency virus ( HIV ) , HBV HCV . Significant ECG abnormality History clinically significant drug allergy heparin , LMWH 's , sevuparin , morphine . Use investigational agent 30 day prior first dose . For female : pregnancy , lactate intention become pregnant Evidence clinically significant disorder might interfere study aim safety subject Any condition , view Investigator , place subject high risk poor treatment compliance complete study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>